KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Minority Interest (2020 - 2025)

AbbVie (ABBV) has disclosed Minority Interest for 6 consecutive years, with $42.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Minority Interest rose 7.69% to $42.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.0 million, a 7.69% increase, with the full-year FY2025 number at $42.0 million, up 7.69% from a year prior.
  • Minority Interest was $42.0 million for Q4 2025 at AbbVie, roughly flat from $42.0 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $43.0 million in Q2 2024 to a low of $23.0 million in Q1 2021.
  • A 5-year average of $34.0 million and a median of $33.0 million in 2022 define the central range for Minority Interest.
  • Peak YoY movement for Minority Interest: skyrocketed 34.78% in 2022, then fell 6.45% in 2023.
  • AbbVie's Minority Interest stood at $28.0 million in 2021, then rose by 17.86% to $33.0 million in 2022, then grew by 12.12% to $37.0 million in 2023, then rose by 5.41% to $39.0 million in 2024, then rose by 7.69% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Minority Interest are $42.0 million (Q4 2025), $42.0 million (Q1 2025), and $39.0 million (Q4 2024).